According to the latest financial report of Santen Pharmaceutical, the latest earnings per share (TTM) for the company is 29.50. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about Santen Pharmaceutical's free cash flow? The latest report shows it as 11.12B. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Santen Pharmaceutical shows that the company's current ratio is 2.54, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Santen Pharmaceutical, the quick ratio is 2.00, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of Santen Pharmaceutical? The latest ROE figure is 0.01%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Santen Pharmaceutical, the total asset return on investment (ROA) is 0.01%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Santen Pharmaceutical's latest financial report to see how their gross margin is doing - currently at 57.20%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Santen Pharmaceutical, the net profit margin is 14.19%, which is a good sign for its profitability.